Trebananib
- Generic Name
- Trebananib
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 894356-79-7
- Unique Ingredient Identifier
- X8Y5U6NC7E
- Background
Trebananib is under investigation for the treatment of Ovarian Cancer, Peritoneal Cancer, and Fallopian Tube Cancer. Trebananib has been investigated for the treatment of Cancer, Oncology, Carcinoma, Metastases, and Colon Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2017-08-03
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 60
- Registration Number
- NCT03239145
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2020-07-01
- Lead Sponsor
- Amgen
- Target Recruit Count
- 85
- Registration Number
- NCT00853372
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath